Discontinued ProductUnfortunately Practolol (Cat. No. 0831) has been withdrawn from sale for commercial reasons.
Cardioselective β-antagonist with weak partial agonism.
Sold with the permission of AstraZeneca UK Ltd.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Preparing Stock Solutions
The following data is based on the product molecular weight 266.34. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.75 mL||18.77 mL||37.55 mL|
|5 mM||0.75 mL||3.75 mL||7.51 mL|
|10 mM||0.38 mL||1.88 mL||3.75 mL|
|50 mM||0.08 mL||0.38 mL||0.75 mL|
References are publications that support the products' biological activity.
View Related Products by Product Action
Keywords: Practolol, supplier, β, beta, adrenoceptor, adrenergic, ICI-50172, Adrenergic, Beta-1, Receptors, Adrenergic, Beta-1, Receptors, Tocris Bioscience
Citations for Practolol
Citations are publications that use Tocris products.
Currently there are no citations for Practolol.
Reviews for Practolol
There are currently no reviews for this product. Be the first to review Practolol and earn rewards!
Have you used Practolol?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.